Debt-to-equity of Landos Biopharma, Inc. from 30 Sep 2021 to 31 Mar 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Landos Biopharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Mar 2024.
  • Landos Biopharma, Inc. Debt-to-equity for the quarter ending 31 Mar 2024 was 16%, a 30% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Landos Biopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2024 16% +4% +30% 31 Mar 2024
Q4 2023 12% -5% -30% 31 Dec 2023
Q3 2023 11% -8% -40% 30 Sep 2023
Q2 2023 11% -7% -38% 30 Jun 2023
Q1 2023 12% -4% -26% 31 Mar 2023
Q4 2022 17% +4% +30% 31 Dec 2022
Q3 2022 19% +1% +5.2% 30 Sep 2022
Q2 2022 18% 30 Jun 2022
Q1 2022 17% 31 Mar 2022
Q4 2021 13% 31 Dec 2021
Q3 2021 18% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.